Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Perform
- Symbol (PHAS)
- Company PhaseBio Pharmaceuticals, Inc.
- Price $0.07
- Changes Percentage (0%)
- Change -$0
- Day Low $0.07
- Day High $0.09
- Year High $0.09
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.38
- Trailing P/E Ratio -0.03
- Forward P/E Ratio -0.03
- P/E Growth -0.03
- Net Income $-131,071
Income Statement
Quarterly
Annual
Latest News of PHAS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Top Kashmir leader says India has silenced dissenting voices as region votes in final phase of polls
Resistance leader Mirwaiz Umar Farooq criticizes Indian-controlled Kashmir's local election, stating it won't resolve the conflict with Pakistan. He emphasizes the election as a festival of democracy ...
By AP NEWS | 16 hours ago -
3 Tricks Our Minds Play On Us In The 'Honeymoon Phase' -- By A Psychologist
The initial rush of a new romance is driven by psychological phenomena such as novelty, uncertainty, and selective focus. These elements create an electrifying mix of emotions, enhancing attraction an...
By Forbes | 2 days ago -
Longboard Pharmaceuticals begins Phase III Dravet syndrome trial
Longboard Pharmaceuticals has started the Phase III DEEp SEA Study for bexicaserin in treating seizures in Dravet syndrome patients. The trial will enroll 160 subjects aged 2-65 to evaluate efficacy a...
By Yahoo! Finance | 3 days ago
